Ratings XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Market Closed - Nasdaq Other stock markets 21:30:01 14/06/2024 BST			5-day change	1st Jan Change
25.16 ^USD	-0.73%		+0.25%	+0.17%

06-12	XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher	MT
05-09	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XOMA CORPORATION	+0.17%	294M	-
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B	B+
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B	B+
ARGENX SE	+5.07%	22.94B	B
BIONTECH SE	-12.75%	22.22B	B+
BEIGENE, LTD.	-9.86%	17.02B	B
GENMAB A/S	-14.97%	16.88B	A-
WUXI APPTEC CO., LTD.	-39.94%	16.87B	A-
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B	C+
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes